cardiac failure

AHA 2019 | DAPA-HF: la dapagliflozina efectiva en todos los subgrupos con insuficiencia cardíaca

AHA 2019 | DAPA-HF: Dapagliflozin Effective for all Heart Failure Subgroups

SGLT2 inhibitor dapagliflozin had a consistent impact regardless of glycemic level, age, or general health status. Dapagliflozin was originally developed for the treatment of type 2 diabetes. However, it has had a positive impact on various types of patients with chronic heart failure and reduced ejection fraction, including those without diabetes. This information is derived from<a href="https://solaci.org/en/2019/11/21/aha-2019-dapa-hf-dapagliflozin-effective-for-all-heart-failure-subgroups/" title="Read more" >...</a>

AHA 2018 | PIONEER-HF: sacubitril/valsartan en insuficiencia cardíaca aguda descompensada

AHA 2018 | PIONEER-HF: Sacubitril/Valsartan in Acute Decompensated Heart Failure

Treating acute decompensated heart failure patients with an angiotensin receptor inhibitor plus a neprilysin receptor inhibitor significantly reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations and clinical events, according to the PIONEER-HF study presented at the American Heart Association (AHA) Congress Scientific Sessions and published simultaneously in the New England Journal of Medicine (NEJM). The study<a href="https://solaci.org/en/2018/11/30/aha-2018-pioneer-hf-sacubitril-valsartan-in-acute-decompensated-heart-failure/" title="Read more" >...</a>

Se publicaron los resultados del estudio RESPECT con excelentes novedades

Liver Failure as a Challenge for TAVR

Although surgical risk scores do not include liver failure (LF), patients who suffer from it and undergo cardiovascular surgery present high rates of morbidity and mortality. This is due to alteration of cardiac function, increased infection susceptibility, gastrointestinal complications, and increased bleeding. As regards transcatheter aortic valve replacement (TAVR), these patients have not been included<a href="https://solaci.org/en/2018/05/03/liver-failure-as-a-challenge-for-tavr/" title="Read more" >...</a>

ACC 2018 | Flu Vaccination Reduces Mortality in Heart Failure Hospitalizations

Heart failure patients vaccinated against influenza are at a significantly lower risk of dying, both during flu season and outside of it. Patients with heart failure vaccinated had a 48% lower risk of death during influenza season and a 21% lower risk during the rest of the year. Dr. Fukuta, lead investigator in this study,<a href="https://solaci.org/en/2018/04/09/acc-2018-flu-vaccination-reduces-mortality-in-heart-failure-hospitalizations/" title="Read more" >...</a>

Cardiac Damage: Should we start to assess it?

Courtesy of Dr. Carlos Fava. The current recommendation for  aortic valve replacement is based on stenosis severity based on valvular criteria (mean transvalvular gradient, peak aortic velocity and valve index area) and the presence of symptoms, in addition to comorbidities, mainly for risk stratification. However, ventricular damage and/or its effect on cardiovascular hemodynamics are not regarded<a href="https://solaci.org/en/2017/12/20/cardiac-damage-should-we-start-to-assess-it/" title="Read more" >...</a>

TRICS III: Restrictive Transfusion Was Noninferior to Liberal Use in Patients Who Undergo Cardiac Surgery

A large study conducted in 19&nbsp;countries has found that a policy of restrictive red-cell transfusion during cardiac surgery is just as safe and effective as more liberal policies. TRICS&nbsp;III enrolled 5243&nbsp;patients and was presented at the American Heart Association (AHA) Scientific Sessions and published simultaneously in the New England Journal of Medicine (NEJM). Patients were<a href="https://solaci.org/en/2017/11/16/trics-iii-restrictive-transfusion-was-noninferior-to-liberal-use-in-patients-who-undergo-cardiac-surgery/" title="Read more" >...</a>

Frecuencia y evolución de la perforación cardíaca en CRM previa

Frequency and Evolution of Cardiac Perforation in Patients with a History of MRS

Courtesy of Dr. Carlos&nbsp;Fava. Coronary perforation (CP) is a very uncommon event (≈0.4%), associated with severe complications that entail risk of death. It has usually been related to patients with a history of myocardial revascularization surgery (MRS). However, this group usually presents lower rates of cardiac tamponade due to pericardial fibrosis caused by surgery. This<a href="https://solaci.org/en/2017/10/05/frequency-and-evolution-of-cardiac-perforation-in-patients-with-a-history-of-mrs/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

Success in CTOs caused by restenosis lowers cardiac mortality

Courtesy of Dr. Carlos&nbsp;Fava. Nowadays, chronic total occlusions (CTO) due to in-stent restenosis (ISR) represent 5%-25% of all coronary angioplasties. These lesions pose a new and true challenge, since CTOs are often associated with stent-related problems (fractures, lack of expansion, overlapping, deformation), extreme tortuosity, severe calcification, tandem lesions after CTO, and aorto-ostial lesions, with little<a href="https://solaci.org/en/2017/06/26/success-in-ctos-caused-by-restenosis-lowers-cardiac-mortality/" title="Read more" >...</a>

ixCELL-DCM: Stem Cell Therapy Improves Outcomes in Patients with Heart Failure

Enhanced autologous bone marrow stem cell therapy improves clinical cardiac events in patients with heart failure and reduced ejection fraction resulting from ischemic heart disease and dilated cardiomyopathy. Globally, percutaneous intra-myocardial delivery of stem cells resulted in a significant 37% reduction in all-cause death, rehospitalization and sudden worsening for heart failure. This study randomized patients<a href="https://solaci.org/en/2016/04/08/ixcell-dcm-stem-cell-therapy-improves-outcomes-in-patients-with-heart-failure/" title="Read more" >...</a>

SCAI Releases Expert Consensus for Cardio-Oncology Patients Treated in Cardiac Catherization Labs

The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus statement providing cardiologists, oncologists and internal medicine physicians guidance for treating patients facing concomitant cardiovascular disease and cancer. The document, “SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catherization Laboratory,” was released in Catheterization and Cardiovascular Interventions (CCI),<a href="https://solaci.org/en/2016/01/19/scai-releases-expert-consensus-for-cardio-oncology-patients-treated-in-cardiac-catherization-labs/" title="Read more" >...</a>

Top